Ground-breaking Insights: Parkinson’s Disease Market Report Delivers Comprehensive Analysis and Future Projections by DelveInsight |Cerevel Therapeutic, Pfizer, Pharma Two B, AbbVie, Biogen, Denali Therapeutics, Annovis Bio, Amneal Pharmaceutical, BioVie

{Delhi, India} To strategically aid Parkinson’s disease companies developing drugs for Parkinson’s disease, DelveInsight launched a report titled as “Parkinson’s disease Market Insight Epidemiology and Market Forecast, 2032”. This comprehensive report delves into epidemiology based market analysis, providing a roadmap for success in the dynamic landscape of Parkinson’s disease market.

Get a free sample of “Parkinson’s disease Market Report”

Parkinson’s disease Market Report’s Key Highlights:

• In the year 2022, the United States recorded the largest Parkinson's disease market size among the 7MM, reaching around USD 1,820 million.
• The United Kingdom reported the lowest Parkinson's disease market size at USD 135 million in 2022.
• Key Parkinson’s disease Companies: Cerevel Therapeutics, Pfizer, Pharma Two B, AbbVie, Biogen, Denali Therapeutics, Annovis Bio, Amneal Pharmaceuticals, BioVie, Cerevance, Clene Nanomedicine, Intra-Cellular Therapies, Hoffmann-La Roche, Prothena Corporation, and others
• Key Parkinson’s disease Therapies: Tavapadon, P2B001, ABBV-951 (foscarbidopa/foslevodopa), BIIB122/DNL151, Buntanetap, IPX203, NE3107, CVN424, CNM-Au8, ITI-214 (lenrispodun), Prasinezumab (RO7046015/RG7935/PRX002), and others.
• The Parkinson’s disease epidemiology based on gender analyzed that higher number of cases of Parkinson’s disease were observed in males as compared to females
• The Parkinson’s disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Parkinson’s disease pipeline products will significantly revolutionize the Parkinson’s disease market dynamics.

Parkinson’s disease Country based Treatment Analysis: 

The Parkinson’s disease treatment market report provides treatment regimen across the 7MM. It will help companies to analyze the practices followed across 7MM, patient journey and advances in Parkinson’s disease Therapies that have the potential to transform cancer treatment paradigms and improve patient outcomes.

Parkinson's disease is a degenerative ailment caused by the loss of nerve cells in the substantia nigra, a region of the brain that governs movement. The cause of Parkinson's disease is unknown, however, it has long been hypothesized that exposure to environmental risk factors, together with a hereditary vulnerability, may be one explanation. The vast majority of instances are assumed to be sporadic, while up to 20% of persons with Parkinson's disease also have a first-degree relative with the disease.

Parkinson's disease is characterized by motor symptoms such as bradykinesia, stiffness, rest tremor, and postural instability. Non-motor symptoms, such as depression, cognitive impairment, pain, and autonomic disturbances, are very common and can have a significant impact on a patient's quality of life. Currently, Parkinson's disease is diagnosed mostly based on the symptoms listed above. There is no X-ray or blood test that can confirm the condition. Noninvasive diagnostic imaging, such as positron emission tomography (PET), can help a doctor make Parkinson's disease diagnosis.

Download the report to understand which factors are driving Parkinson’s disease epidemiology trends @ Parkinson’s disease Epidemiology Forecast

Parkinson’s disease Epidemiology Insights: 

The report proffers historical and forecasted epidemiology insights that helps to understand the target patient population for Parkinson’s disease. The analysis is from 2019-2032, providing insights how the patient trends are going to shape the market dynamics. Further, the epidemiology is segmented to provide in-depth analysis of patient pools allowing companies to understand their target patients pools. The epidemiology in report is segmented as : 

Parkinson’s disease Epidemiology Segmentation:

• Total Prevalence of Parkinson’s disease
• Prevalent Cases of Parkinson’s disease by severity
• Gender-specific Prevalence of Parkinson’s disease
• Diagnosed Cases of Episodic and Chronic Parkinson’s disease

“DelveInsight estimates that there were approximately 2.5 million diagnosed prevalent cases of Parkinson's disease in the 7MM in 2022. This number is predicted to rise at a moderate annual growth rate (CAGR) by 2032.”

Parkinson’s disease Therapies and Key Companies

• Tavapadon: Cerevel Therapeutics
• P2B001: Pharma Two B
• ABBV-951: AbbVie
• BIIB122: Biogen
• Buntanetap: Annovis Bio
• IPX203: Amneal Pharmaceuticals
• NE3107: BioVie
• CVN424: Cerevance
• ITI-214: Intra-Cellular Therapies
• CNM-Au8: Clene Nanomedicine

Emerging Parkinson’s disease drugs Uptake:

• SPN-830 (apomorphine infusion device) is an investigational apomorphine infusion device under review for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson’s disease patients that are not adequately controlled with oral levodopa and one or more adjunct Parkinson's disease medications. SPN-830 is an SC formulation of apomorphine delivered continuously through a portable electronic infusion pump under the skin for 14–18 h. Recently, the US FDA accepted the NDA filed by Supernus Pharmaceuticals for SPN-830, with the scheduled PDUFA date in 2024. In 2022, the US FDA had issued a CRL to Supernus Pharmaceutical for the SPN-830 NDA, which was filled in September 2020. Prior to this also it had filed an NDA for which it received refusal to file (RTF) letter. The drug completed a Phase III trial, and the company is anticipated to launch the SPN-830 in 2024.
• Cerevel Therapeutics/Pfizer is currently conducting Phase III trials of tavapadon, known as TEMPO-1, TEMPO-2, and TEMPO-3, as monotherapy (early-stage) and adjunctive (late-stage) in Parkinson’s disease. It is also conducting an open-label extension trial known as TEMPO-4. Cerevel expects data from the TEMPO-3 trial by the first half of 2024, while data from TEMPO-1 and TEMPO-2 is anticipated by the second half of 2024.
• A plethora of medications is under development. These include drugs that specifically target α-synuclein pathology, widely considered to be the driver of neurodegeneration in Parkinson’s disease. These drugs offer hope for disease-modifying agents in the short- to medium-term future. In combination with several regenerative approaches, including stem cells and gene therapies, therapeutics for Parkinson’s disease are likely to see significant advances over the coming years, with several novel, effective options likely to become available in the foreseeable future.

 To know more about Parkinson’s disease companies working in the treatment market, visit @ Parkinson’s disease Clinical Trials and Therapeutic Assessment

 Parkinson’s disease Market Forecast:

• The research includes a thorough analysis of the past and projected markets for Parkinson’s disease, which includes pharmacological outreach in the 7MM nations.
• The ongoing research have led to better understanding of Parkinson's disease and discover innovative treatments with novel technologies and route of administration like infusion pump, intranasal, inhalation, intraputaminal, etc.
• Rising prevalence and an increasing aging population result in a larger target pool for the Parkinson’s disease companies.

Discover more about therapies set to grab major Parkinson’s disease market share @ Parkinson’s disease Treatment Market

Scope of the Parkinson’s disease Market Report: 

• Geography Coverage: 7MM
• Study Period: 2019-2032
• Parkinson’s disease Market Size: ~USD 2,936.3 million in 2022
• Key Parkinson’s disease Companies: Cerevel Therapeutics, Pfizer, Pharma Two B, AbbVie, Biogen, Denali Therapeutics, Annovis Bio, Amneal Pharmaceuticals, BioVie, Cerevance, Clene Nanomedicine, Intra-Cellular Therapies, Hoffmann-La Roche, Prothena Corporation, and others.

Note: 

DelveInsight's report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Parkinson’s disease market landscape.

• Gain Competitive Edge in Indication Market : Understand the current landscape of the Parkinson’s disease market, including the competitive environment, key companies developing drugs for Parkinson’s disease , and their strategies. By analyzing market dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.
• Identify Market Gaps and indication market opportunities : Analyzing epidemiological trends, country wise patient journeys and existing tretment practices can helps in identifying gaps and opportunities within the Parkinson’s disease market. This involves recognizing areas where current treatments may be insufficient or where there is an unmet need. The report is curated by taking account of various KOLs dealing with Parkinson’s disease. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.
• Strategic decision making : Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing - reimbursement strategies, partnerships, or other strategic moves. Understanding the market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.
• Plan RoadMap to Success : Through this report the leading companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the Parkinson’s disease market with clarity and purpose.

Related Reports

Parkinson's Disease Epidemiology Forecast

Parkinson's Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and Parkinson's disease epidemiology trends.

Parkinson's Disease Pipeline

Parkinson's Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Parkinson's disease companies, including Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., among others.

Psychosis in Parkinson's and Alzheimer's Disease Market

Psychosis in Parkinson's and Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psychosis in Parkinson's and Alzheimer's disease companies, including Sunovion Pharmaceuticals, Karuna Therapeutics, Vanda Pharmaceuticals, Suven Life Sciences, Enterin, Intra-Cellular Therapies, Merck Sharp & Dohme, among others.

Parkinson's Disease-Related Dementia Market

Parkinson's Disease-Related Dementia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease-related dementia companies, including AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., among others. 

Do you want to know how we helped our client Navigating the Asia-Pacific Life Sciences Landscape through Strategic Competitive Benchmarking: Download case study today!

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Assistant Manager Marketing

Email: info@delveinsight.com

Website: https://www.delveinsight.com/consulting